Neutralizes heparin-like molecules on endothelial surfaces, promoting coagulation by inhibiting antithrombin III .
Binds heparin with higher affinity than chondroitin sulfate, enhancing clot stability .
Chemotaxis: Attracts neutrophils, monocytes, and fibroblasts via integrin Mac-1 (CD11b/CD18) .
Anti-inflammatory Effects: Reduces pro-inflammatory cytokine release in liver macrophages and promotes activated Protein C (APC) generation, mitigating acute liver injury .
Bacterial Clearance: Enhances phagocytosis of Staphylococcus aureus by macrophages and neutrophils, improving survival in murine peritonitis models .
Accelerates wound healing by moderating angiogenesis (inhibits FGF and VEGF signaling) .
Rejuvenates hippocampal neurogenesis in aged mice, improving cognitive function .
Liver Disease: PF4 attenuates experimental liver injury by modulating macrophage activity .
Infections: Augments host defense against methicillin-resistant S. aureus (MRSA) .
Aging: Reverses age-related declines in hematopoietic stem cell function and cognitive capacity .
Cancer: Inhibits tumor angiogenesis by blocking FGF dimerization and VEGF receptor signaling .
Dosage: Effective in vivo doses range from 40 µg/mL (cell studies) to 500 ng (tail vein injections in mice) .
Stability: Lyophilized PF4 remains stable at -80°C for 12 months; reconstituted solutions retain activity for 1 week at 4°C .